

**American College of Radiology  
ACR Appropriateness Criteria®  
Soft Tissue Masses**

**Variant 1: Superficial soft tissue mass. Initial imaging.**

Procedure	Appropriateness Category	Relative Radiation Level
US area of interest	Usually Appropriate	O
Radiography area of interest	Usually Appropriate	Varies
US area of interest with IV contrast	Usually Not Appropriate	O
Image-guided biopsy area of interest	Usually Not Appropriate	Varies
Image-guided fine needle aspiration area of interest	Usually Not Appropriate	Varies
MRI area of interest without and with IV contrast	Usually Not Appropriate	O
MRI area of interest without IV contrast	Usually Not Appropriate	O
FDG-PET/CT area of interest	Usually Not Appropriate	⊕⊕⊕⊕
CT area of interest with IV contrast	Usually Not Appropriate	Varies
CT area of interest without and with IV contrast	Usually Not Appropriate	Varies
CT area of interest without IV contrast	Usually Not Appropriate	Varies

**Variant 2: Nonsuperficial (deep) soft tissue mass. Initial imaging.**

Procedure	Appropriateness Category	Relative Radiation Level
Radiography area of interest	Usually Appropriate	Varies
US area of interest	May Be Appropriate	O
CT area of interest with IV contrast	May Be Appropriate	Varies
CT area of interest without and with IV contrast	May Be Appropriate	Varies
CT area of interest without IV contrast	May Be Appropriate	Varies
US area of interest with IV contrast	Usually Not Appropriate	O
Image-guided biopsy area of interest	Usually Not Appropriate	Varies
Image-guided fine needle aspiration area of interest	Usually Not Appropriate	Varies
MRI area of interest without and with IV contrast	Usually Not Appropriate	O
MRI area of interest without IV contrast	Usually Not Appropriate	O
FDG-PET/CT area of interest	Usually Not Appropriate	⊕⊕⊕⊕

**Variant 3: Soft tissue mass. Nondiagnostic radiograph and noncontrast-enhanced ultrasound. Next imaging study.**

Procedure	Appropriateness Category	Relative Radiation Level
MRI area of interest without and with IV contrast	Usually Appropriate	○
MRI area of interest without IV contrast	May Be Appropriate	○
CT area of interest with IV contrast	May Be Appropriate	Varies
CT area of interest without and with IV contrast	May Be Appropriate	Varies
US area of interest with IV contrast	Usually Not Appropriate	○
Image-guided biopsy area of interest	Usually Not Appropriate	Varies
Image-guided fine needle aspiration area of interest	Usually Not Appropriate	Varies
FDG-PET/CT area of interest	Usually Not Appropriate	☼☼☼☼
CT area of interest without IV contrast	Usually Not Appropriate	Varies

**Variant 4: Soft tissue mass. Nondiagnostic radiograph and noncontrast-enhanced ultrasound. MRI contraindicated. Next imaging study.**

Procedure	Appropriateness Category	Relative Radiation Level
CT area of interest with IV contrast	Usually Appropriate	Varies
CT area of interest without and with IV contrast	May Be Appropriate	Varies
US area of interest with IV contrast	Usually Not Appropriate	○
Image-guided biopsy area of interest	Usually Not Appropriate	Varies
Image-guided fine needle aspiration area of interest	Usually Not Appropriate	Varies
FDG-PET/CT area of interest	Usually Not Appropriate	☼☼☼☼
CT area of interest without IV contrast	Usually Not Appropriate	Varies

## SOFT TISSUE MASSES

Expert Panel on Musculoskeletal Imaging: Hillary W. Garner, MD<sup>a</sup>; Daniel E. Wessell, MD, PhD<sup>b</sup>; Leon Lenchik, MD<sup>c</sup>; Shivani Ahlawat, MD<sup>d</sup>; Jonathan C. Baker, MD<sup>e</sup>; James Banks, MD<sup>f</sup>; Jennifer L. Demertzis, MD<sup>g</sup>; Bryan S. Moon, MD<sup>h</sup>; Jennifer L. Pierce, MD<sup>i</sup>; Jinel A. Scott, MD, MBA<sup>j</sup>; Neema K. Sharda, MD<sup>k</sup>; Devaki Shilpa Surasi, MD<sup>l</sup>; Michael Temporal, MD<sup>m</sup>; Eric Y. Chang, MD.<sup>n</sup>

### Summary of Literature Review

#### **Introduction/Background**

A variety of benign and malignant processes may present clinically as a soft tissue mass. The behavior of a mass, whether nonaggressive, indeterminant, or aggressive, can often be discerned based on history and physical examination. However, when a benign clinical diagnosis cannot be confidently provided, further characterization of a soft tissue mass with imaging is warranted [1]. Urgent imaging requests should be sought for masses that are >5 cm in diameter, deep in location, or have shown rapid growth [2]. Modern imaging techniques allow for a detailed analysis of the morphology of a soft tissue mass as well as further insight into its biologic activity, which informs the interpreter on diagnosis and appropriate next steps in management [3,4].

The purpose of this document is to identify the most appropriate imaging study(ies) to order for the assessment of a soft tissue mass based on the most frequently encountered clinical scenarios in medical practice. The rationale for the level of appropriateness granted to each study option is also described in accordance with the current literature and the consensus opinion of the members of the ACR Appropriateness Criteria Expert Panel on Musculoskeletal Imaging. This document does not address follow-up recommendations for patients with previously diagnosed masses or the appropriate approach or techniques for the imaging-guided biopsy of known masses. The former is covered by a separate ACR Appropriateness Criteria document [4], whereas the latter requires direct communication with the clinician or orthopedic oncologist supervising and coordinating patient care.

Of note, soft tissue sarcomas are rare, representing <1% of all malignancies [5]. Therefore, we must emphasize a fundamental tenet of orthopedic oncology: if a "...practitioner, or the institution, is not equipped to perform accurate diagnostic studies or definitive operative and adjunctive treatment ... then it is in the patient's best interest to be referred to a treatment center before performance of the biopsy" [6,7]. This tenet has been recently supported by a large retrospective analysis of 25,406 patients with soft tissue sarcoma of the extremities that found lower risk of positive margins and mortality in patients treated at high-volume orthopedic oncology centers (>20 soft tissue sarcoma patients annually) compared with low-volume centers [8].

#### **Initial Imaging Definition**

Initial imaging is defined as imaging at the beginning of the care episode for the medical condition defined by the variant. More than one procedure can be considered usually appropriate in the initial imaging evaluation when:

- There are procedures that are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care)

OR

- There are complementary procedures (ie, more than one procedure is ordered as a set or simultaneously where each procedure provides unique clinical information to effectively manage the patient's care).

---

<sup>a</sup>Mayo Clinic Florida, Jacksonville, Florida. <sup>b</sup>Panel Chair, Mayo Clinic, Jacksonville, Florida. <sup>c</sup>Panel Vice-Chair, Wake Forest University School of Medicine, Winston Salem, North Carolina. <sup>d</sup>Johns Hopkins University School of Medicine, Baltimore, Maryland. <sup>e</sup>Mallinckrodt Institute of Radiology Washington University School of Medicine, Saint Louis, Missouri. <sup>f</sup>Nova Southeastern University, Fort Lauderdale, Florida. <sup>g</sup>Diagnostic Imaging Associates, Chesterfield, Missouri. <sup>h</sup>The University of Texas MD Anderson Cancer Center, Houston, Texas; American Academy of Orthopaedic Surgeons. <sup>i</sup>University of Virginia, Charlottesville, Virginia. <sup>j</sup>SUNY Downstate Health Sciences University, Brooklyn, New York. <sup>k</sup>Duke University School of Medicine, Durham, North Carolina; American Geriatrics Society. <sup>l</sup>The University of Texas MD Anderson Cancer Center, Houston, Texas; Commission on Nuclear Medicine and Molecular Imaging. <sup>m</sup>Billings Clinic, Billings, Montana; American Academy of Family Physicians. <sup>n</sup>Specialty Chair, VA San Diego Healthcare System, San Diego, California.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through representation of such organizations on expert panels. Participation on the expert panel does not necessarily imply endorsement of the final document by individual contributors or their respective organization.

Reprint requests to: [publications@acr.org](mailto:publications@acr.org)

## **Discussion of Procedures by Variant**

### **Variant 1: Superficial soft tissue mass. Initial imaging.**

The body regions covered in this clinical scenario include the neck, chest, abdomen, pelvis, humerus/upper arm, shoulder, elbow, forearm, wrist, hand, hip, femur/thigh, knee, tibia/lower leg, ankle, and foot.

#### **Radiography Area of Interest**

Initial imaging assessment of a suspected musculoskeletal soft tissue mass should almost invariably begin with radiographic evaluation and is advocated by the European Society for Medical Oncology–European Reference Network Clinical Practice Guidelines for rare adult solid cancers (ESMO-EURACAN) [9]. Although often considered unrewarding by clinicians without musculoskeletal expertise, a study of the radiographic evaluation of 454 patients with proven soft tissue masses demonstrated positive results in 62% of cases, with calcification identified in 27% of cases, bone involvement in 22% of cases, and intrinsic fat in 11% of cases [10]. Specifically, radiographic findings can be diagnostic or highly characteristic, such as in the identification of phleboliths within a hemangioma, the osteocartilaginous masses of synovial chondromatosis, or the peripherally more mature ossification of myositis ossificans, to name just a few. In addition, radiographs can be diagnostic of an unsuspected skeletal abnormality or deformity that may manifest as a soft tissue mass. Even when a specific diagnosis cannot be provided, radiographs may reveal information on the type and scope of mineralization, the presence or absence of unsuspected foreign matter, or changes within the adjacent bone. In general, radiographic findings related to a soft tissue mass can provide helpful insight in determining the next most appropriate imaging modality for further characterization. Of note, radiographs may not demonstrate an associated abnormality when a mass is small, deep-seated, nonmineralized, or in an area with complex anatomy such as the flank, paraspinal region, groin, or deep soft tissues of the hands and feet [11].

#### **US Area of Interest**

Ultrasound (US) has become increasingly recognized as an excellent triage tool for evaluation of superficial soft tissue masses [12-15]. This recognition has been further supported by a recent prospective study of 219 histologically proven masses that showed US had a sensitivity, specificity, positive predictive value, and negative predictive value of 93.3%, 97.9%, 45.2%, and 99.9%, respectively, for discriminating benign from malignant tumors in the superficial soft tissues [16]. The same group of researchers had similar results in an earlier separate retrospective analysis of 247 histologically proven masses [17]. However, although these results highlight the benefits of US in the initial assessment of superficial masses, the overall number of malignancies in both the prospective [16] and retrospective [17] studies was very small (12 patients and 11 patients, respectively). Another recent study of 42 histologically proven masses concluded that MRI performed after US does not frequently change the working diagnosis or add diagnostic value, but again, this study only included a small number of malignancies and the value of MRI for these malignancies was not separately addressed in the study [18]. Therefore, we emphasize that these studies do not have sufficient power for showing high accuracy of US in the diagnosis of malignancy. Ultimately, US is most beneficial for triage, and when US features are not clearly benign or when history and physical examination findings are otherwise concerning, further imaging is required [9,19].

#### **US Area of Interest With IV Contrast**

The use of intravenous (IV) contrast during US evaluation of soft tissue tumors may add further confidence in discriminating benign from indeterminate or malignant masses [20-22]. However, there is no literature showing that the addition of contrast provides a gain in diagnostic accuracy over standard grayscale and Doppler US features in the assessment of a soft tissue mass. Therefore, the literature does not support the use of US contrast in the initial examination of a superficial soft tissue mass.

#### **MRI Area of Interest Without and With IV Contrast**

There is insufficient literature to support the routine use of MRI without or with IV contrast as the initial examination for a soft tissue mass. The inherent limitations of this modality, most notably in the identification of mineralization, limit its use in isolation.

#### **MRI Area of Interest Without IV Contrast**

There is insufficient literature to support the routine use of MRI without IV contrast as the initial examination for a soft tissue mass. The inherent limitations of this modality, most notably in the identification of mineralization, limit its use in isolation.

#### **CT Area of Interest With IV Contrast**

CT with IV contrast does not typically play a role in the initial evaluation of a superficial soft tissue mass.

### **CT Area of Interest Without and With IV Contrast**

CT does not typically play a role in the initial evaluation of a superficial soft tissue mass.

### **CT Area of Interest Without IV Contrast**

CT does not typically play a role in the initial evaluation of a superficial soft tissue mass.

### **FDG-PET/CT Area of Interest**

There is insufficient literature to support the routine use of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT for the initial evaluation of a soft tissue mass.

### **Image-Guided Biopsy Area of Interest**

The literature does not support the use of image-guided biopsy as the initial examination for a soft tissue mass. At least 20% to 25% of soft tissue masses can demonstrate features that allow for confident diagnosis based on MRI alone [23], many of which are benign and thus would not warrant biopsy. Therefore, diagnostic imaging that includes comprehensive characterization of the mass should routinely be performed before biopsy. In fact, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma state that biopsy should be performed only after adequate imaging [24].

### **Image-Guided Fine Needle Aspiration Area of Interest**

The literature does not support the use of image-guided fine needle aspiration as the initial examination for a soft tissue mass. At least 20% to 25% of soft tissue masses can demonstrate features that allow for confident diagnosis based on MRI alone [23], many of which are benign and thus would not warrant fine needle aspiration. Therefore, diagnostic imaging that includes comprehensive characterization of the mass should routinely be performed before biopsy. In fact, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma state that biopsy or fine needle aspiration should be performed only after adequate imaging [24].

### **Variant 2: Nonsuperficial (deep) soft tissue mass. Initial imaging.**

The body regions covered in this clinical scenario include the neck, chest, abdomen, pelvis, humerus/upper arm, shoulder, elbow, forearm, wrist, hand, hip, femur/thigh, knee, tibia/lower leg, ankle, and foot.

### **Radiography Area of Interest**

Initial imaging assessment of a suspected musculoskeletal soft tissue mass should almost invariably begin with radiographic evaluation and is advocated by ESMO-EURACAN [9]. Radiographs remain the modality best suited for the initial assessment of a suspected soft tissue mass and are the initial study of choice for orthopedic oncologists [25,26]. However, radiographs have limitations and may not reveal an abnormality when a mass is small, deep-seated, nonmineralized, or in an area with complex anatomy such as the flank, paraspinal region, groin, or deep soft tissues of the hands and feet [11].

### **US Area of Interest**

The diagnostic accuracy of US is considerably less when lesions outside the subcutaneous tissue are included. It is also less reliable for defining deep masses in large anatomical areas [27]. Although a recent prospective study of US accuracy in the characterization of 134 histologically proven deep soft tissue masses showed promising results, there were only a small number of malignancies in the study cohort, and the investigators had a high level of US expertise [28]. Therefore, US is most appropriate for superficial masses that are small (<5 cm) in size [13] but may be appropriate for deep soft tissue masses in specific settings, such as a deep mass in a thin patient.

### **US Area of Interest With IV Contrast**

The diagnostic accuracy of US is considerably less when lesions outside the subcutaneous tissue are included. It is also less reliable for defining deep masses in large anatomical areas [27]. Although an assessment of diagnostic accuracy of US with IV contrast in the setting of a deep soft tissue mass is not available in the current literature, there is presumably no added benefit over standard grayscale and Doppler US. Therefore, the US with IV contrast is not useful for the initial assessment of deep soft tissue masses.

### **MRI Area of Interest Without and With IV Contrast**

The current radiology, orthopedic oncology, and surgical oncology literature does not support the use of MRI without and with IV as the initial examination for a soft tissue mass.

### **MRI Area of Interest Without IV Contrast**

The current radiology, orthopedic oncology, and surgical oncology literature does not support the use of MRI without IV contrast as the initial examination for a soft tissue mass.

### **CT Area of Interest With IV Contrast**

CT with IV contrast does not typically play a role in the initial evaluation of a deep soft tissue mass. However, CT can be useful in areas where the osseous anatomy is complex or obscured for the distinction of ossification from calcification and the identification of characteristic patterns of mineralization [29,30]. In anatomically complex areas where radiographs would be less sensitive, CT may be beneficial as the initial or complementary imaging modality. Fortunately, the advent of virtual noncontrast reconstruction with modern dual-source CT scanners allows for acquisition of a single postcontrast scan with reconstruction of virtual noncontrast images, which can preclude the need for a separate precontrast scan phase [31].

For myositis ossificans, CT is superior to radiography in detecting the zonal pattern of mineralization, which is essential for early diagnosis [11]. In addition, CT allows for differentiation of soft tissue masses based on lesion density and can delineate vascular and bone involvement [29,30]. This differentiation may be better defined by immediately repeating the scan after contrast administration. During the assessment of cortical remodeling or invasion, the character of the interface between a soft tissue mass and the adjacent osseous cortex can usually be visualized to better advantage with CT compared to radiographs.

### **CT Area of Interest Without and With IV Contrast**

CT without and with IV contrast does not typically play a role in the initial evaluation of a deep soft tissue mass. However, CT can be useful in areas where the osseous anatomy is complex or obscured for the distinction of ossification from calcification and the identification of characteristic patterns of mineralization [29,30]. In anatomically complex areas where radiographs would be less sensitive, CT may be beneficial as the initial or complementary imaging modality. Fortunately, the advent of virtual noncontrast reconstruction with modern dual-source CT scanners allows for acquisition of a single postcontrast scan with reconstruction of virtual noncontrast images, which can preclude the need for a separate precontrast scan phase [31].

For myositis ossificans, CT is superior to radiography in detecting the zonal pattern of mineralization, which is essential for early diagnosis [11]. In addition, CT allows for differentiation of soft tissue masses based on lesion density and can delineate vascular and bone involvement [29,30]. This differentiation may be better defined by immediately repeating the scan after contrast administration. During the assessment of cortical remodeling or invasion, the character of the interface between a soft tissue mass and the adjacent osseous cortex can usually be visualized to better advantage with CT compared to radiographs.

### **CT Area of Interest Without IV Contrast**

CT without IV contrast does not typically play a role in the initial evaluation of a deep soft tissue mass. However, CT can be useful in areas where the osseous anatomy is complex or obscured for the distinction of ossification from calcification and the identification of characteristic patterns of mineralization [29,30]. In anatomically complex areas where radiographs would be less sensitive, CT may be beneficial as the initial or complementary imaging modality. Fortunately, the advent of virtual noncontrast reconstruction with modern dual-source CT scanners allows for acquisition of a single postcontrast scan with reconstruction of virtual noncontrast images, which can preclude the need for a separate precontrast scan phase [31].

For myositis ossificans, CT is superior to radiography in detecting the zonal pattern of mineralization, which is essential for early diagnosis [11]. In addition, CT allows for differentiation of soft tissue masses based on lesion density and can delineate vascular and bone involvement [29,30]. This differentiation may be better defined by immediately repeating the scan after contrast administration. During the assessment of cortical remodeling or invasion, the character of the interface between a soft tissue mass and the adjacent osseous cortex can usually be visualized to better advantage with CT compared to radiographs.

### **FDG-PET/CT Area of Interest**

FDG PET/CT does not typically play a role in the initial evaluation of a soft tissue mass. The CT component associated with PET/CT is of lower resolution compared with conventional CT and is not optimal for accurate characterization of soft tissue mineralization.

### **Image-Guided Biopsy Area of Interest**

The literature does not support the use of image-guided biopsy as the initial examination for a soft tissue mass. At least 20% to 25% of soft tissue masses can demonstrate features that allow for confident diagnosis based on MRI alone [23], many of which are benign and thus would not warrant biopsy. Therefore, diagnostic imaging that includes comprehensive characterization of the mass should routinely be performed before biopsy. In fact, the

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma state that biopsy should be performed only after adequate imaging [24].

### **Image-Guided Fine Needle Aspiration Area of Interest**

The literature does not support the use of image-guided fine needle aspiration as the initial examination for a soft tissue mass. At least 20% to 25% of soft tissue masses can demonstrate features that allow for confident diagnosis based on MRI alone [23], many of which are benign and thus would not warrant fine needle aspiration. Therefore, diagnostic imaging that includes comprehensive characterization of the mass should routinely be performed before biopsy. In fact, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma state that biopsy or fine needle aspiration should be performed only after adequate imaging [24].

### **Variant 3: Soft tissue mass. Nondiagnostic radiograph and noncontrast-enhanced ultrasound. Next imaging study.**

The body regions covered in this clinical scenario include the neck, chest, abdomen, pelvis, humerus/upper arm, shoulder, elbow, forearm, wrist, hand, hip, femur/thigh, knee, tibia/lower leg, ankle, and foot.

Of note, this variant addresses the scenario in which radiographs and/or noncontrast US have been performed but did not sufficiently characterize a soft tissue mass. In addition, this variant presumes there are no contraindications to any imaging modality. Variant 4 specifically addresses the situation of a contraindication to MRI.

### **CT Area of Interest With IV Contrast**

Although CT with IV contrast lacks the specificity afforded by MRI in many cases, it does provide useful staging data [32]. In a multi-institutional study of 133 patients with primary soft tissue malignancies, Panicek et al [32] found no statistically significant difference between MRI and contrast-enhanced CT imaging in determining tumor involvement of muscle, bone, joint, or neurovascular structures. Therefore, CT with IV contrast remains an important adjunct in the evaluation of a soft tissue mass.

The advent of virtual noncontrast reconstruction with modern dual-source CT scanners allows for acquisition of a single postcontrast scan with reconstruction of virtual noncontrast images, which can preclude the need for a separate precontrast scan phase [31]. Similar to CT without IV contrast [21, 22], virtual noncontrast imaging allows distinction of ossification from calcification and identification of characteristic patterns of mineralization [29,30] and is particularly useful in assessment of mass mineralization in areas where the osseous anatomy is complex or obscured and radiographs would be less sensitive.

### **CT Area of Interest Without and With IV Contrast**

The advent of virtual noncontrast reconstruction with modern dual-source CT scanners allows for acquisition of a single postcontrast scan with reconstruction of virtual noncontrast images, which can preclude the need for a separate precontrast scan phase [31]. However, a traditional CT without and with IV contrast may be appropriate for characterization of mineralization in an anatomically complex area. Although a multi-institutional study of 133 patients with primary soft tissue malignancies by Panicek et al [32] found no statistically significant difference between MRI and contrast-enhanced CT imaging in determining tumor involvement of muscle, bone, joint, or neurovascular structures, this study did not specifically endorse the usefulness of dual-phase CT without and with IV contrast. CT with IV contrast remains an important adjunct in the evaluation of a soft tissue mass.

### **CT Area of Interest Without IV Contrast**

The literature does not support the use of single-phase CT without IV contrast as the next imaging study for the evaluation of a soft tissue mass. Although a multi-institutional study of 133 patients with primary soft tissue malignancies by Panicek et al [32] found no statistically significant difference between MRI and contrast-enhanced CT imaging in determining tumor involvement of muscle, bone, joint, or neurovascular structures, this study did not endorse the usefulness of single-phase CT without IV contrast.

### **MRI Area of Interest Without and With IV Contrast**

MRI without and with IV contrast is the technique of choice as the next imaging study for the evaluation of soft tissue masses. Its improved soft tissue contrast and multiplanar capability have provided significant advantages for lesion conspicuity, intrinsic tumor characterization, and local staging [3,11]. Vascular structures and neurovascular involvement are more easily defined when compared with CT.

The use of MR contrast agents improves the differentiation of benign from malignant soft tissue masses [33]. The contrast allows for better demarcation between viable tumor and muscle, edema-like reactive change, hemorrhage, and tumor necrosis, as well as providing information on tumor vascularity.

In addition to static MR contrast imaging, there are several additional modern MR techniques that provide greater insight into the character and behavior of soft tissue masses and can assist with differentiation of benign from malignant tumors. These include diffusion-weighted imaging [34-37], dynamic contrast-enhanced perfusion imaging [38,39], and MR spectroscopy [38,39]. Of note, chemical-shift imaging has not shown utility in differentiating benign from malignant soft tissue masses [40]. However, the Dixon technique will likely be increasingly recognized as beneficial for soft tissue tumor imaging through its potential to provide more homogenous fat suppression when compared to traditional T2-fat saturated imaging and better resolution than inversion recovery imaging. Furthermore, it may help decrease imaging time because the Dixon water-only and fat-only images are acquired simultaneously [41,42].

#### **MRI Area of Interest Without IV Contrast**

MRI without IV contrast may be beneficial as the next imaging study for the evaluation of soft tissue masses. Its improved soft tissue contrast and multiplanar capability have provided significant advantages for lesion conspicuity, intrinsic tumor characterization, and local staging [3,11]. Vascular structures and neurovascular involvement are more easily defined when compared with CT.

The use of MR contrast agents improves the differentiation of benign from malignant soft tissue masses [33]. The contrast allows for better demarcation between viable tumor and muscle, edema-like reactive change, hemorrhage, and tumor necrosis, as well as providing information on tumor vascularity.

In addition to static MR contrast imaging, there are several additional modern MR techniques that provide greater insight into the character and behavior of soft tissue masses and can assist with differentiation of benign from malignant tumors. These include diffusion-weighted imaging [34-37], dynamic contrast-enhanced perfusion imaging [38,39], and MR spectroscopy [38,39]. Of note, chemical-shift imaging has not shown utility in differentiating benign from malignant soft tissue masses [40]. However, the Dixon technique will likely be increasingly recognized as beneficial for soft tissue tumor imaging through its potential to provide more homogenous fat suppression when compared to traditional T2-fat saturated imaging and better resolution than inversion recovery imaging. Furthermore, it may help decrease imaging time because the Dixon water-only and fat-only images are acquired simultaneously [41,42].

#### **FDG-PET/CT Area of Interest**

As a general rule, PET/CT imaging maximum standard uptake value can be useful for differentiating between benign and malignant musculoskeletal masses. When combined with anatomic data provided by CT, FDG-PET/CT can be useful in distinguishing aggressive soft tissue tumors from benign lesions [43-45]. Benz et al [46] showed that FDG-PET can be used to determine a tumor glycolytic phenotype in sarcomas, which correlates significantly with histologic grade. Fused FDG-PET/CT images can be used to plan biopsy, targeting areas with more metabolic activity that may give higher diagnostic yield. Furthermore, a meta-analysis found that FDG-PET can be a helpful tool for predicting outcome in patients with soft tissue sarcoma [47]. Lastly, FDG-PET/CT is an excellent modality to detect metastatic disease and assess treatment response [48]. Despite these benefits, FDG-PET/CT does not usually play a role as the next imaging study for the characterization of a soft tissue mass when initial radiographs or US are nondiagnostic.

#### **Image-Guided Biopsy Area of Interest**

The literature does not support the use of image-guided biopsy as the next step in evaluation following nondiagnostic radiographs or US of a soft tissue mass. At least 20% to 25% of soft tissue masses can demonstrate features that allow for confident diagnosis based on MRI alone [23], many of which are benign and thus would not warrant biopsy. Therefore, diagnostic imaging that includes comprehensive characterization of the mass should routinely be performed before biopsy. In fact, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma state that biopsy should be performed only after adequate imaging [24].

#### **Image-Guided Fine Needle Aspiration Area of Interest**

The literature does not support the use of image-guided fine needle aspiration as the next step in evaluation following nondiagnostic radiographs or US of a soft tissue mass. At least 20% to 25% of soft tissue masses can demonstrate features that allow for confident diagnosis based on MRI alone [23], many of which are benign and



thus would not warrant biopsy. Therefore, diagnostic imaging that includes comprehensive characterization of the mass should routinely be performed before biopsy. In fact, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma state that biopsy should be performed only after adequate imaging [24].

#### **US Area of Interest With IV Contrast**

Although prospective studies have emerged suggesting that US is accurate in the discrimination of benign from malignant soft tissue masses, the number of malignancies in these studies was limited [16,28]. Therefore, the use of US for the final evaluation and staging of a deep soft tissue mass is not recommended.

#### **Variant 4: Soft tissue mass. Nondiagnostic radiograph and noncontrast-enhanced ultrasound. MRI contraindicated. Next imaging study.**

The body regions covered in this clinical scenario include the neck, chest, abdomen, pelvis, humerus/upper arm, shoulder, elbow, forearm, wrist, hand, hip, femur/thigh, knee, tibia/lower leg, ankle, and foot.

#### **CT Area of Interest With IV Contrast**

CT has become a useful technique for the evaluation of patients who cannot undergo MRI and is the modality of choice in this scenario [29]. In the evaluation of suspected tumors, contrast imaging is especially useful in distinguishing vascularized from potentially necrotic regions of the tumor. With modern CT technology, calcification can usually be distinguished from vascular enhancement.

Of note, dual-energy CT is a relatively newer technology that has shown utility in evaluation of soft tissue masses. Using the differences in energy attenuation of soft tissue at 80 kVp and 140 kVp, this technique can allow reconstruction of virtual noncontrast CT images as well as significantly reduce metal artifact in the assessment of metal implants, improving the diagnostic value of imaging in the surrounding soft tissues [49,50]. It has also shown application in the assessment of marrow edema [51,52] and has been investigated in the distinction of marrow edema from intramedullary tumor invasion [53]. Furthermore, spectral CT is emerging as a useful tool for distinguishing benign from malignant soft tissue masses [54].

#### **CT Area of Interest Without and With IV Contrast**

Dual-phase CT without and with IV contrast as the next imaging study for the evaluation of a soft tissue mass may be appropriate when MRI is contraindicated. Although single-phase CT with IV contrast is considered most appropriate in this clinical scenario given the advent of virtual noncontrast reconstruction with modern dual-source CT scanners [31], a traditional CT without and with IV contrast can be helpful for characterization of mineralization in an anatomically complex area.

#### **CT Area of Interest Without IV Contrast**

The literature does not support the use of a single-phase CT without IV contrast as the next imaging study for the evaluation of a soft tissue mass when MRI is contraindicated. However, single-phase CT with IV contrast is a useful technique for the evaluation of patients who cannot undergo MRI and is the modality of choice in this scenario [29]. In the evaluation of suspected tumors, contrast imaging is especially useful in distinguishing vascularized from potentially necrotic regions of the tumor. With modern CT technology, calcification can usually be distinguished from vascular enhancement. Therefore, CT without IV contrast is usually not beneficial.

#### **FDG-PET/CT Area of Interest**

Although FDG-PET/CT is not typically used as the next imaging study for the characterization of a soft tissue mass, PET/CT imaging maximum standard uptake value can be useful for differentiating between benign and malignant musculoskeletal masses. When combined with anatomic data provided by CT, FDG-PET/CT can be useful in distinguishing aggressive soft tissue tumors from benign lesions [43-45]. Benz et al [46] showed that FDG-PET can be used to determine a tumor glycolytic phenotype in sarcomas, which correlates significantly with histologic grade. Fused FDG-PET/CT images can be used to plan biopsy, targeting areas with more metabolic activity that may give higher diagnostic yield. Furthermore, a meta-analysis found that FDG-PET can be a helpful tool for predicting outcome in patients with soft tissue sarcoma [47]. Lastly, FDG-PET/CT is an excellent modality to detect metastatic disease and assess treatment response [48]. Despite these benefits, FDG-PET/CT does not usually play a role in the initial assessment of a soft tissue mass.

#### **Image-Guided Biopsy Area of Interest**

The literature does not support the use of image-guided biopsy as the next step in evaluation following nondiagnostic radiographs or US of a soft tissue mass. If MRI is contraindicated, characterization of the mass using

CT with IV contrast should routinely be performed before biopsy [29]. In fact, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma state that biopsy should be performed only after adequate imaging [24].

### Image-Guided Fine Needle Aspiration Area of Interest

The literature does not support the use of image-guided fine needle aspiration as the next step in evaluation following nondiagnostic radiographs or US of a soft tissue mass. If MRI is contraindicated, characterization of the mass using CT with IV contrast should routinely be performed before biopsy [29]. In fact, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma state that biopsy should be performed only after adequate imaging [24].

### US Area of Interest With IV Contrast

There is insufficient literature to support the routine use of US with IV contrast as the next imaging study for the evaluation of a soft tissue mass when MRI is contraindicated.

### Summary of Recommendations

- **Variation 1:** US or radiography are usually appropriate for the initial imaging of a superficial soft tissue mass.
- **Variation 2:** Radiography is usually appropriate for the initial imaging of a nonsuperficial (deep) soft tissue mass.
- **Variation 3:** MRI without and with IV contrast is usually appropriate as the next imaging study for a soft tissue mass following nondiagnostic radiographs or noncontrast-enhanced US.
- **Variation 4:** When MRI is contraindicated, CT with IV contrast is usually appropriate as the next imaging study for a soft tissue mass following nondiagnostic radiographs or noncontrast-enhanced US.

### Supporting Documents

The evidence table, literature search, and appendix for this topic are available at <https://acsearch.acr.org/list>. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents go to [www.acr.org/ac](http://www.acr.org/ac).

### Appropriateness Category Names and Definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel’s recommendation. “May be appropriate” is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

## Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared with those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#) document [55].

Relative Radiation Level Designations		
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
○	0 mSv	0 mSv
☼	<0.1 mSv	<0.03 mSv
☼☼	0.1-1 mSv	0.03-0.3 mSv
☼☼☼	1-10 mSv	0.3-3 mSv
☼☼☼☼	10-30 mSv	3-10 mSv
☼☼☼☼☼	30-100 mSv	10-30 mSv

\*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies.”

## References

1. Roland CL. Soft Tissue Tumors of the Extremity. *Surg Clin North Am* 2020;100:669-80.
2. Rochwerger A, Mattei JC. Management of soft tissue tumors of the musculoskeletal system. *Orthop Traumatol Surg Res* 2018;104:S9-S17.
3. Murphey MD, Kransdorf MJ. Staging and Classification of Primary Musculoskeletal Bone and Soft-Tissue Tumors According to the 2020 WHO Update, From the AJR Special Series on Cancer Staging. *AJR Am J Roentgenol* 2021;217:1038-52.
4. Roberts CC, Kransdorf MJ, Beaman FD, et al. ACR Appropriateness Criteria Follow-Up of Malignant or Aggressive Musculoskeletal Tumors. *J Am Coll Radiol* 2016;13:389-400.
5. Fletcher C, Mertens F. The WHO Classification of Tumours Editorial Board. *WHO Classification of Tumours. Soft Tissue and Bone Tumours*. 5th ed: Lyon: IARC Press; 2020.
6. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. *J Bone Joint Surg Am* 1982;64:1121-7.
7. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. *J Bone Joint Surg Am* 1996;78:656-63.
8. Lazarides AL, Kerr DL, Nussbaum DP, et al. Soft Tissue Sarcoma of the Extremities: What Is the Value of Treating at High-volume Centers? *Clin Orthop Relat Res* 2019;477:718-27.
9. Casali PG, Abecassis N, Aro HT, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018;29:iv51-iv67.
10. Gartner L, Pearce CJ, Saifuddin A. The role of the plain radiograph in the characterisation of soft tissue tumours. *Skeletal Radiol* 2009;38:549-58.
11. Kransdorf MJ, Murphey MD. Imaging of Soft-Tissue Musculoskeletal Masses: Fundamental Concepts. *Radiographics* 2016;36:1931-48.
12. Aparisi Gomez MP, Errani C, Lalam R, et al. The Role of Ultrasound in the Diagnosis of Soft Tissue Tumors. *Semin Musculoskelet Radiol* 2020;24:135-55.
13. Wagner JM, Rebik K, Spicer PJ. Ultrasound of Soft Tissue Masses and Fluid Collections. *Radiol Clin North Am* 2019;57:657-69.

14. Gruber L, Gruber H, Luger AK, Glodny B, Henninger B, Loizides A. Diagnostic hierarchy of radiological features in soft tissue tumours and proposition of a simple diagnostic algorithm to estimate malignant potential of an unknown mass. *Eur J Radiol* 2017;95:102-10.
15. Jacobson JA, Middleton WD, Allison SJ, et al. Ultrasonography of Superficial Soft-Tissue Masses: Society of Radiologists in Ultrasound Consensus Conference Statement. *Radiology* 2022;211101.
16. Hung EHY, Griffith JF, Yip SWY, et al. Accuracy of ultrasound in the characterization of superficial soft tissue tumors: a prospective study. *Skeletal Radiol* 2020;49:883-92.
17. Hung EH, Griffith JF, Ng AW, Lee RK, Lau DT, Leung JC. Ultrasound of musculoskeletal soft-tissue tumors superficial to the investing fascia. *AJR Am J Roentgenol* 2014;202:W532-40.
18. Goldman LH, Perronne L, Alaia EF, et al. Does Magnetic Resonance Imaging After Diagnostic Ultrasound for Soft Tissue Masses Change Clinical Management? *J Ultrasound Med* 2021;40:1515-22.
19. Carra BJ, Bui-Mansfield LT, O'Brien SD, Chen DC. Sonography of musculoskeletal soft-tissue masses: techniques, pearls, and pitfalls. *AJR Am J Roentgenol* 2014;202:1281-90.
20. De Marchi A, Prever EBD, Cavallo F, et al. Perfusion pattern and time of vascularisation with CEUS increase accuracy in differentiating between benign and malignant tumours in 216 musculoskeletal soft tissue masses. *Eur J Radiol* 2015;84:142-50.
21. Gruber L, Loizides A, Luger AK, et al. Soft-Tissue Tumor Contrast Enhancement Patterns: Diagnostic Value and Comparison Between Ultrasound and MRI. *AJR Am J Roentgenol* 2017;208:393-401.
22. Loizides A, Peer S, Plaikner M, Djurdjevic T, Gruber H. Perfusion pattern of musculoskeletal masses using contrast-enhanced ultrasound: a helpful tool for characterisation? *Eur Radiol* 2012;22:1803-11.
23. Manaster BJ. Soft-tissue masses: optimal imaging protocol and reporting. *AJR Am J Roentgenol* 2013;201:505-14.
24. von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2018;16:536-63.
25. Sherman CE, O'Connor MI. Musculoskeletal tumor imaging: an orthopedic oncologist perspective. *Semin Musculoskelet Radiol* 2013;17:221-6.
26. Wilke BK, Goulding KA, Sherman CE, Houdek MT. Soft Tissue Tumors: Diagnosis, Treatment, and Follow-up from the Orthopedic Oncologist Perspective. *Radiol Clin North Am* 2022;60:253-62.
27. Lakkaraju A, Sinha R, Garikipati R, Edward S, Robinson P. Ultrasound for initial evaluation and triage of clinically suspicious soft-tissue masses. *Clin Radiol* 2009;64:615-21.
28. Griffith JF, Yip SWY, Hung EHY, et al. Accuracy of ultrasound in the characterisation of deep soft tissue masses: a prospective study. *Eur Radiol* 2020;30:5894-903.
29. Mayerson JL, Scharschmidt TJ, Lewis VO, Morris CD. Diagnosis and Management of Soft-tissue Masses. *J Am Acad Orthop Surg* 2014;22:742-50.
30. Subhawong TK, Fishman EK, Swart JE, Carrino JA, Attar S, Fayad LM. Soft-tissue masses and masslike conditions: what does CT add to diagnosis and management? *AJR Am J Roentgenol* 2010;194:1559-67.
31. Holz JA, Alkadhi H, Laukamp KR, et al. Quantitative accuracy of virtual non-contrast images derived from spectral detector computed tomography: an abdominal phantom study. *Sci Rep* 2020;10:21575.
32. Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. *Radiology* 1997;202:237-46.
33. van Rijswijk CS, Geirnaerd MJ, Hogendoorn PC, et al. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. *Radiology* 2004;233:493-502.
34. Boruah DK, Gogoi B, Patni RS, Sarma K, Hazarika K. Added Value of Diffusion-Weighted Magnetic Resonance Imaging in Differentiating Musculoskeletal Tumors Using Sensitivity and Specificity: A Retrospective Study and Review of Literature. *Cureus* 2021;13:e12422.
35. Choi YJ, Lee IS, Song YS, Kim JI, Choi KU, Song JW. Diagnostic performance of diffusion-weighted (DWI) and dynamic contrast-enhanced (DCE) MRI for the differentiation of benign from malignant soft-tissue tumors. *J Magn Reson Imaging* 2019;50:798-809.
36. Lee JH, Kim HS, Yoon YC, et al. Characterization of small, deeply located soft-tissue tumors: Conventional magnetic resonance imaging features and apparent diffusion coefficient for differentiation between non-malignancy and malignancy. *PLoS One* 2020;15:e0232622.
37. Lee SK, Jee WH, Jung CK, Chung YG. Multiparametric quantitative analysis of tumor perfusion and diffusion with 3T MRI: differentiation between benign and malignant soft tissue tumors. *Br J Radiol* 2020;93:20191035.

38. Bruno F, Arrigoni F, Mariani S, et al. Advanced magnetic resonance imaging (MRI) of soft tissue tumors: techniques and applications. *Radiol Med* 2019;124:243-52.
39. Dodin G, Salleron J, Jendoubi S, et al. Added-value of advanced magnetic resonance imaging to conventional morphologic analysis for the differentiation between benign and malignant non-fatty soft-tissue tumors. *Eur Radiol* 2021;31:1536-47.
40. Saifuddin A, Siddiqui S, Pressney I, Khoo M. The incidence and diagnostic relevance of chemical shift artefact in the magnetic resonance imaging characterisation of superficial soft tissue masses. *Br J Radiol* 2020;93:20190828.
41. Pezeshk P, Alian A, Chhabra A. Role of chemical shift and Dixon based techniques in musculoskeletal MR imaging. *Eur J Radiol* 2017;94:93-100.
42. Valenzuela RF, Madewell JE, Kundra V, Costelloe CM. Advanced Imaging in Musculoskeletal Oncology: Moving Away From RECIST and Embracing Advanced Bone and Soft Tissue Tumor Imaging (ABASTI)-Part II-Novel Functional Imaging Techniques. *Semin Ultrasound CT MR* 2021;42:215-27.
43. Bischoff M, Bischoff G, Buck A, et al. Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors. *Arch Orthop Trauma Surg* 2010;130:819-27.
44. Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors. *Ann Nucl Med* 2008;22:603-9.
45. Chen B, Feng H, Xie J, Li C, Zhang Y, Wang S. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing (18)F-FDG PET/CT-derived parameters. *BMC Med Imaging* 2020;20:85.
46. Benz MR, Dry SM, Eilber FC, et al. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. *J Nucl Med* 2010;51:1174-81.
47. Kubo T, Furuta T, Johan MP, Ochi M. Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis. *Eur J Cancer* 2016;58:104-11.
48. Jackson T, Mosci C, von Eyben R, et al. Combined 18F-NaF and 18F-FDG PET/CT in the Evaluation of Sarcoma Patients. *Clin Nucl Med* 2015;40:720-4.
49. Bamberg F, Dierks A, Nikolaou K, Reiser MF, Becker CR, Johnson TR. Metal artifact reduction by dual energy computed tomography using monoenergetic extrapolation. *Eur Radiol* 2011;21:1424-9.
50. D'Angelo T, Cicero G, Mazziotti S, et al. Dual energy computed tomography virtual monoenergetic imaging: technique and clinical applications. *Br J Radiol* 2019;92:20180546.
51. Peltola EK, Koskinen SK. Dual-energy computed tomography of cruciate ligament injuries in acute knee trauma. *Skeletal Radiol* 2015;44:1295-301.
52. Reagan AC, Mallinson PI, O'Connell T, et al. Dual-energy computed tomographic virtual noncalcium algorithm for detection of bone marrow edema in acute fractures: early experiences. *J Comput Assist Tomogr* 2014;38:802-5.
53. Chen H, Jia M, Xu W. Malignant bone tumor intramedullary invasion: evaluation with dual-energy computed tomography in a rabbit model. *J Comput Assist Tomogr* 2015;39:70-4.
54. Sun X, Shao X, Chen H. The value of energy spectral CT in the differential diagnosis between benign and malignant soft tissue masses of the musculoskeletal system. *Eur J Radiol* 2015;84:1105-8.
55. American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. Available at: <https://www.acr.org/-/media/ACR/Files/Appropriateness-Criteria/RadiationDoseAssessmentIntro.pdf>. Accessed November 30, 2022.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.